Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Trial ID or NCT#
NCT01020305
Status
NOT RECRUITING
Purpose
This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
Official Title
Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
SandyÌýSrinivas
Medical oncologist,
Urologic specialist,
Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology
Stefanie S. Jeffrey, MD
Contact us to find out if this trial is right for you.
Contact
Denise Haas
6507361252
View on